Home Contact Us Links  
  News   R&D  
Products
R&D
Operations
Downloads
 
     
 

C- VAD™

Contolled Therapeutics is also developing the C-Vad™ controlled-release vaginal insert to treat bacterial vaginosis. Bacterial vaginosis is one of the three most common vaginal infections in women. It is usually caused by an imbalance of the normally existing microorganisms living in the vagina. It may cause vaginal discharge and an unpleasant odor. Recent studies also suggest that bacterial vaginosis may be implicated in some cases of pre-term labour.

The C-Vad™ vaginal insert delivers a measured amount of the antibiotic clindamycin over a 24-hour period. Clindamycin is currently used for the

   
 

C-VAD
>> Click to enlarge

 

treatment of bacterial vaginosis in cream, ovule and oral formulations. Each of these formulations has drawbacks: oral clindamycin often causes significant side effects, while the vaginal cream and ovule formulations may leak out, resulting in discomfort, embarrassment and underdosing. Controlled Therapeutic’s vaginal delivery system reduces systemic exposure and, therefore, side effects. It also delivers the drug in a precise dose, without the inconvenience of a cream or ovule.

 
  bullet point Phase I
       
     
  bullet point Phase II
  bullet point

The C Vad™ Vaginal Insert

  bullet point

The Pilobuc™ Buccal Insert

     
  bullet point Phase III
  bullet point

The Misopess® Vaginal Insert

     
     
 
 
bottom